Neoplasia — MCQs
On this page
Which of the following statements is false regarding tumor hypoxia?
Teratoma is best described as:
The BCR-ABL hybrid gene is characteristically present in which of the following conditions?
What is the most important prognostic factor for breast carcinoma?
A 60-year-old male presents with hematuria and weight loss. Cystoscopy biopsy of a superficial lesion in the bladder shows hyperchromatic nuclei, an increased nuclear-to-cytoplasmic ratio. The lesion involves the full thickness of the epithelium but does not invade the basement membrane. What is the diagnosis?
What of the following is essential for tumor metastasis?
Squamous papilloma is induced by?
The most common histologic type of carcinoma of the oral cavity is?
Which gene is involved in Gastrointestinal Stromal Tumors (GIST)?
Malignant neoplasms show all the following features EXCEPT?
Neoplasia Indian Medical PG Practice Questions and MCQs
Question 31: Which of the following statements is false regarding tumor hypoxia?
- A. Hypoxia in tumors can result from two different mechanisms: chronic hypoxia and acute hypoxia.
- B. Acute hypoxia is caused by a temporary closing of a blood vessel in the tumor.
- C. Chronic hypoxia is caused by the limited diffusion distance of oxygen through tissue that is respiring.
- D. Oxygen does not affect the radiosensitivity of tumors. (Correct Answer)
Explanation: ### Explanation **1. Why Option D is the correct (False) statement:** The **Oxygen Enhancement Ratio (OER)** is a fundamental principle in radiotherapy. Oxygen acts as a **radiosensitizer**. When ionizing radiation hits tissue, it creates free radicals (like hydroxyl radicals) that damage DNA. In the presence of oxygen, these damages are "fixed" or made permanent through the formation of peroxyl radicals. In hypoxic conditions, cells are significantly more resistant to radiation (often 2–3 times more resistant) because the DNA damage can be more easily repaired [1]. Therefore, saying oxygen does *not* affect radiosensitivity is factually incorrect. **2. Analysis of other options:** * **Option A & B (Acute Hypoxia):** This is true. Also known as **perfusion-limited hypoxia**, it occurs due to the malformed, leaky, and disorganized nature of tumor vasculature, which can lead to transient vessel collapse or spontaneous shunting. * **Option C (Chronic Hypoxia):** This is true. Also known as **diffusion-limited hypoxia**, it occurs because oxygen can only diffuse approximately **70–150 µm** from a capillary. Cells beyond this distance become hypoxic and eventually necrotic (forming the classic "palisading" pattern seen in Glioblastoma). **3. Clinical Pearls for NEET-PG:** * **HIF-1α (Hypoxia-Inducible Factor):** Under hypoxic conditions, HIF-1α is not degraded; it translocates to the nucleus to activate genes for **VEGF** (angiogenesis) and **GLUT1** (anaerobic glycolysis/Warburg effect). * **VHL Protein:** In the presence of oxygen, the VHL protein targets HIF-1α for ubiquitination. Loss of VHL (as in Von Hippel-Lindau syndrome) leads to constitutive HIF activation and highly vascular tumors (e.g., Renal Cell Carcinoma). * **Reoxygenation:** One goal of fractionated radiotherapy is to allow hypoxic cells to become reoxygenated between doses, making them more susceptible to the next round of radiation [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Central Nervous System Synapse, pp. 436-437.
Question 32: Teratoma is best described as:
- A. A hamartous developmental manifestation consisting of three different germ layers (Correct Answer)
- B. Occurs most commonly in the ovary and testis
- C. Originates from pluripotent cells capable of differentiating into all three germ layers
- D. Often associated with increased levels of alpha-fetoprotein (AFP)
Explanation: A **Teratoma** is a true neoplasm composed of tissues derived from more than one germ layer—usually all three: **ectoderm, mesoderm, and endoderm** [1], [2]. While technically a neoplasm, it is fundamentally described as a **hamartomatous developmental manifestation** because it consists of mature or immature cells/tissues (like hair, teeth, bone, or respiratory epithelium) that are foreign to the anatomical site where they arise [1]. **2. Analysis of Incorrect Options:** * **Option B:** While the ovary and testis are common sites, the **most common site** for teratomas overall (especially in infants) is the **sacrococcygeal region**. * **Option C:** This is a description of the *origin* of teratomas (totipotent/pluripotent germ cells) [4]. However, the question asks for the best *description* of the lesion itself, which is its multi-germinal, hamartomatous nature. * **Option D:** AFP is a marker for **Yolk Sac Tumors** [3]. While a *malignant* teratoma might show elevated AFP if it has yolk sac components, a pure teratoma typically does not. **High-Yield NEET-PG Pearls:** * **Sacrococcygeal Teratoma:** Most common germ cell tumor in childhood; more common in females. * **Ovarian Teratoma:** Usually benign (Dermoid cyst) [1], [2]. * **Testicular Teratoma:** In adults, these are considered **malignant** regardless of histological maturity [3]. * **Monodermal Teratomas:** Specialized versions like **Struma ovarii** (thyroid tissue) or **Carcinoid** [4]. * **Grading:** Immature teratomas are graded based on the amount of **immature neuroepithelium**. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Female Genital Tract Disease, pp. 480-481. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1033-1034. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 979-980. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, p. 1034.
Question 33: The BCR-ABL hybrid gene is characteristically present in which of the following conditions?
- A. Burkitt's lymphoma
- B. Retinoblastoma
- C. Breast carcinoma
- D. Chronic myeloid leukemia (CML) (Correct Answer)
Explanation: ### Explanation **Correct Answer: D. Chronic myeloid leukemia (CML)** The **BCR-ABL hybrid gene** is the molecular hallmark of Chronic Myeloid Leukemia (CML) [1], [2]. It results from a reciprocal translocation between chromosomes 9 and 22, denoted as **t(9;22)(q34;q11)** [3]. This shortened chromosome 22 is famously known as the **Philadelphia (Ph) chromosome** [3]. * **Mechanism:** The *ABL* proto-oncogene (Chr 9) fuses with the *BCR* gene (Chr 22), creating a chimeric protein with constitutive **tyrosine kinase activity** [1]. This leads to uncontrolled proliferation of the myeloid lineage. **Analysis of Incorrect Options:** * **A. Burkitt’s Lymphoma:** Characterized by the translocation **t(8;14)**, which leads to the overexpression of the **c-MYC** proto-oncogene. * **B. Retinoblastoma:** Associated with the inactivation or deletion of the **RB1 tumor suppressor gene** located on chromosome **13q14** (Knudson’s two-hit hypothesis). * **C. Breast Carcinoma:** Frequently associated with mutations in **BRCA1/BRCA2** genes or amplification of the **HER2/neu** (ERBB2) proto-oncogene, but not the BCR-ABL fusion. **High-Yield Clinical Pearls for NEET-PG:** * **Targeted Therapy:** **Imatinib mesylate**, a tyrosine kinase inhibitor (TKI), specifically targets the BCR-ABL protein and is the first-line treatment for CML [2]. * **Variant Fusions:** While the p210 protein is classic for CML, the **p190** isoform is often seen in **Ph+ Acute Lymphoblastic Leukemia (ALL)**, which carries a poorer prognosis. * **Diagnosis:** Gold standard for detection is **FISH** (Fluorescence In Situ Hybridization) or **RT-PCR** [3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 624. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 295-296. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 225-226.
Question 34: What is the most important prognostic factor for breast carcinoma?
- A. Age of the patient
- B. Lymph node involvement (Correct Answer)
- C. Genetic factors
- D. Family history
Explanation: **Explanation:** In the management of breast carcinoma, determining the prognosis is essential for deciding the aggressiveness of therapy. **1. Why Lymph Node Involvement is Correct:** Axillary lymph node status is the **single most important prognostic factor** for invasive breast carcinoma in the absence of distant metastasis [1]. The presence or absence of nodal involvement correlates directly with the risk of recurrence and overall survival [2]. The number of involved nodes also provides a quantitative measure of prognosis (e.g., 1–3 nodes vs. >10 nodes) [1]. It reflects the tumor's ability to spread via the lymphatic system, which usually precedes hematogenous dissemination. **2. Why Other Options are Incorrect:** * **Age of the patient (A):** While younger patients (under 35) often present with more aggressive subtypes (like Triple Negative), age is a secondary factor compared to the anatomical extent of the disease. * **Genetic factors (C):** Mutations like *BRCA1* or *BRCA2* increase the **risk** (predisposition) of developing breast cancer but do not dictate the prognosis as heavily as the stage at diagnosis. * **Family history (D):** Similar to genetic factors, this is a significant **risk factor** for the occurrence of the disease but is not a primary determinant of the clinical outcome once the cancer has developed. **High-Yield Clinical Pearls for NEET-PG:** * **Most important prognostic factor:** Axillary lymph node status [1]. * **Most important factor for "staging":** Tumor size and lymph node status (TNM staging) [3]. * **Sentinel Lymph Node Biopsy (SLNB):** The gold standard for initial nodal assessment in clinically node-negative patients to avoid the morbidity of full axillary dissection [1]. * **Distant Metastasis:** If present, it becomes the most important prognostic factor (Stage IV), but among localized/regional disease, lymph nodes remain paramount [3]. * **HER2/neu & Hormone Receptors:** These are crucial **predictive factors** (determining response to specific therapies like Trastuzumab or Tamoxifen). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1070-1072. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 458-459. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1072.
Question 35: A 60-year-old male presents with hematuria and weight loss. Cystoscopy biopsy of a superficial lesion in the bladder shows hyperchromatic nuclei, an increased nuclear-to-cytoplasmic ratio. The lesion involves the full thickness of the epithelium but does not invade the basement membrane. What is the diagnosis?
- A. Dysplasia
- B. Metaplasia
- C. Bladder carcinoma in situ (Correct Answer)
- D. Micro invasion
Explanation: ### Explanation **Correct Answer: C. Bladder carcinoma in situ (CIS)** **Why it is correct:** The diagnosis of **Carcinoma in situ (CIS)** is based on two critical histopathological criteria described in the stem: 1. **Cytological Malignancy:** The presence of hyperchromatic nuclei and an increased nuclear-to-cytoplasmic (N:C) ratio indicates high-grade cellular atypia. 2. **Extent and Invasiveness:** The atypia involves the **full thickness** of the epithelium, but the **basement membrane remains intact** [1]. By definition, CIS represents a pre-invasive stage where malignant cells have not yet breached the basement membrane to access the underlying stroma (lamina propria) [2]. **Why other options are incorrect:** * **A. Dysplasia:** While dysplasia also involves cytological atypia, it is typically categorized as low or high grade and often does not involve the full thickness of the epithelium. CIS is considered the most advanced form of dysplasia [1]. * **B. Metaplasia:** This is a reversible change where one adult cell type is replaced by another (e.g., squamous metaplasia in the bladder due to chronic irritation). It does not inherently imply malignancy or high N:C ratios. * **D. Micro invasion:** This term is used when malignant cells have breached the basement membrane and invaded the stroma, even if only by a small amount (usually <3mm depending on the organ). The stem explicitly states there is no invasion [2]. **NEET-PG High-Yield Pearls:** * **CIS of the Bladder:** Unlike papillary urothelial tumors, CIS is a **flat lesion** [2]. It is often multifocal and carries a high risk of progression to muscle-invasive bladder cancer (MIBC) [2]. * **Hallmark of Malignancy:** The definitive distinction between CIS and invasive carcinoma is the **integrity of the basement membrane** [1]. * **Clinical Presentation:** Hematuria in an elderly male should always raise suspicion for urothelial malignancy [2]. Smoking is the most significant risk factor. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 209-210. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 970-972.
Question 36: What of the following is essential for tumor metastasis?
- A. Angiogenesis (Correct Answer)
- B. Tumorogenesis
- C. Apoptosis
- D. Inhibition of tyrosine kinase activity
Explanation: **Explanation:** **Why Angiogenesis is Correct:** For a tumor to grow beyond 1–2 mm in diameter and eventually metastasize, it must develop its own blood supply [1], [3]. **Angiogenesis** (the formation of new blood vessels) is essential for metastasis for two primary reasons: 1. **Nutrient Supply:** It provides the oxygen and nutrients required for the primary tumor to expand [1]. 2. **Access to Circulation:** New "leaky" tumor vessels provide a route for malignant cells to enter the systemic circulation (intravasation), allowing them to travel to distant organs [3]. This process is mediated by the "Angiogenic Switch," primarily driven by **VEGF** (Vascular Endothelial Growth Factor) and **FGF** [1]. **Analysis of Incorrect Options:** * **B. Tumorogenesis:** This refers to the initial formation of a tumor (transformation of a normal cell to a neoplastic one). While it is the starting point of cancer, it is a prerequisite for the tumor's existence, not a specific mechanism that facilitates the spread (metastasis) to distant sites. * **C. Apoptosis:** This is programmed cell death. Metastatic cells must actually **evade** apoptosis (specifically *anoikis*, which is death induced by loss of cell adhesion) to survive in the bloodstream [3]. * **D. Inhibition of tyrosine kinase activity:** Tyrosine kinases (like EGFR or HER2) often promote cell growth and survival. Inhibiting them would generally **suppress** tumor progression and metastasis rather than facilitate it. **High-Yield Clinical Pearls for NEET-PG:** * **HIF-1α:** A transcription factor produced in response to hypoxia that stimulates VEGF production [1]. * **Thrombospondin-1:** An important endogenous **inhibitor** of angiogenesis; its loss promotes the angiogenic switch [1]. * **Bevacizumab:** A monoclonal antibody against VEGF used clinically to inhibit angiogenesis in various cancers. * **Metastatic Cascade:** Key steps include dissociation (loss of E-cadherin), degradation of ECM (MMPs/Type IV Collagenase), and intravasation [2], [4]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 313-314. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 314-315. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 233-234. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 232-233.
Question 37: Squamous papilloma is induced by?
- A. EBV
- B. HSV
- C. HPV (Correct Answer)
- D. CMV
Explanation: **Explanation:** **Squamous papilloma** is a benign neoplastic proliferation of stratified squamous epithelium. It is primarily induced by the **Human Papillomavirus (HPV)** [1], specifically the low-risk genotypes **HPV-6 and HPV-11** [1]. These viruses infect basal keratinocytes [3], leading to characteristic finger-like projections (papillae) supported by fibrovascular cores [2,5]. **Why HPV is the correct answer:** HPV proteins **E6 and E7** interfere with tumor suppressor proteins p53 and RB, respectively [4]. In low-risk types (6, 11), this interference leads to benign cellular proliferation rather than malignant transformation [1]. A hallmark histological finding is **koilocytosis** (squamous cells with perinuclear halos and wrinkled "raisin-like" nuclei) [2,5]. **Why other options are incorrect:** * **EBV (Epstein-Barr Virus):** Associated with Nasopharyngeal carcinoma, Burkitt lymphoma [1], and Oral Hairy Leukoplakia (which is non-papillomatous). * **HSV (Herpes Simple Virus):** Causes vesicular and ulcerative lesions (e.g., cold sores or genital herpes) characterized by Cowdry Type A inclusion bodies and multinucleated giant cells, not papillomas. * **CMV (Cytomegalovirus):** Typically causes systemic infections in immunocompromised states, characterized by "Owl’s eye" intranuclear inclusions. **High-Yield NEET-PG Pearls:** * **HPV 6 & 11:** Cause Squamous Papilloma, Condyloma Acuminatum (genital warts), and Laryngeal Papillomatosis [1]. * **HPV 16 & 18:** High-risk types associated with Squamous Cell Carcinoma of the cervix, oropharynx, and anus [1,4]. * **Koilocytes:** Pathognomonic for HPV infection [2]; found in the superficial layers of the epithelium. * **Morphology:** Grossly described as "cauliflower-like" or "exophytic" growths [5]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 219-220. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Female Genital Tract Disease, pp. 466-467. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1007-1008. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1006-1007. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1177-1178.
Question 38: The most common histologic type of carcinoma of the oral cavity is?
- A. Adenocarcinoma
- B. Clear cell carcinoma
- C. Large cell undifferentiated carcinoma
- D. Squamous cell carcinoma (Correct Answer)
Explanation: **Explanation:** **Correct Answer: D. Squamous cell carcinoma** **1. Why Squamous Cell Carcinoma (SCC) is correct:** The oral cavity is lined by **stratified squamous epithelium**. Neoplasia most frequently arises from the cells that normally constitute the tissue of origin. Chronic exposure to carcinogens—most notably **tobacco (smoking/chewing)**, **alcohol**, and **betel quid**—induces dysplastic changes in these squamous cells, eventually leading to malignancy [1]. Consequently, SCC accounts for over **90-95%** of all oral cavity cancers. The most common site is the lower lip, followed by the lateral border of the tongue and the floor of the mouth [1], [3]. **2. Why the other options are incorrect:** * **A. Adenocarcinoma:** These arise from glandular epithelium. In the oral cavity, they originate from minor salivary glands. While they occur, they are significantly less common than SCC. * **B. Clear cell carcinoma:** This is a rare variant of salivary gland tumors (like Mucoepidermoid carcinoma or Clear cell adenocarcinoma) and is not the predominant type for the oral cavity. * **C. Large cell undifferentiated carcinoma:** This is a histological pattern more commonly associated with the lungs or specific nasopharyngeal sites, rather than the primary oral cavity [2]. **3. NEET-PG High-Yield Pearls:** * **Precursor Lesions:** Leukoplakia (white patch) and Erythroplakia (red patch). Erythroplakia has a much higher risk of malignant transformation [3]. * **Field Cancerization:** This concept explains why patients with one oral SCC are at high risk for developing independent primary tumors in the upper aerodigestive tract due to diffuse mucosal exposure to carcinogens. * **HPV Association:** While tobacco is the leading cause, **HPV-16** is an increasingly important risk factor, particularly for oropharyngeal cancers (tonsils/base of tongue) [1]. * **Histology:** Look for "Keratin pearls" and "Intercellular bridges" on biopsy slides to identify well-differentiated SCC. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 738-739. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 744-745. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 737-738.
Question 39: Which gene is involved in Gastrointestinal Stromal Tumors (GIST)?
- A. C-KIT (Correct Answer)
- B. BRAC-1
- C. p53
- D. BRAC-2
Explanation: **Explanation:** **1. Why C-KIT is Correct:** Gastrointestinal Stromal Tumors (GIST) are the most common mesenchymal tumors of the GI tract, arising from the **Interstitial Cells of Cajal (ICC)**—the "pacemakers" of the gut. Approximately **85-90%** of GISTs are driven by gain-of-function mutations in the **c-KIT (CD117)** proto-oncogene [1], which encodes a receptor tyrosine kinase. This mutation leads to constitutive activation of the kinase, promoting uncontrolled cell proliferation [1]. A smaller subset (approx. 5-10%) involves mutations in the **PDGFRA** gene [1]. **2. Why Other Options are Incorrect:** * **BRCA-1 & BRCA-2:** These are tumor suppressor genes involved in DNA repair (homologous recombination). Mutations are primarily associated with hereditary **Breast and Ovarian Cancer** syndromes, not mesenchymal GI tumors. * **p53:** Known as the "Guardian of the Genome," this is the most commonly mutated tumor suppressor gene in human cancers (e.g., Li-Fraumeni syndrome). While it may be involved in the progression of many tumors, it is not the primary diagnostic driver for GIST. **3. High-Yield Clinical Pearls for NEET-PG:** * **Diagnostic Marker:** **CD117** is the most sensitive and specific immunohistochemical (IHC) marker for GIST. **DOG1** (Discovered on GIST-1) is another highly specific marker. * **Morphology:** GISTs can show **Spindle cell** (most common) or **Epithelioid** patterns. * **Targeted Therapy:** The discovery of c-KIT mutations revolutionized treatment. **Imatinib mesylate** (a tyrosine kinase inhibitor) is the first-line targeted therapy for unresectable or metastatic GIST. * **Location:** The **Stomach** (60%) is the most common site, followed by the small intestine [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 782-783.
Question 40: Malignant neoplasms show all the following features EXCEPT?
- A. Disorganized cell structure
- B. Encapsulation (Correct Answer)
- C. Invasion of blood vessels
- D. Rapid, erratic growth
Explanation: ### Explanation The hallmark of malignancy is the ability to breach natural tissue boundaries and spread to distant sites. [2] **Why "Encapsulation" is the correct answer:** Encapsulation is a characteristic feature of **benign tumors**. As benign tumors grow slowly, they compress the surrounding stroma, leading to the formation of a fibrous capsule. [3] This capsule keeps the tumor localized and mobile. In contrast, **malignant neoplasms** are characterized by an infiltrative growth pattern. [2] They lack a true capsule and send out "crab-like" extensions into the surrounding stroma, making them fixed and difficult to remove surgically without wide margins. [2] **Analysis of Incorrect Options:** * **Disorganized cell structure:** Malignant cells exhibit **anaplasia** (lack of differentiation). [1] This includes pleomorphism (variation in size/shape), increased nuclear-to-cytoplasmic (N:C) ratio, and loss of polarity. [1] * **Invasion of blood vessels:** This is a definitive sign of malignancy. [1] Lymphatic and hematogenous spread (invasion into vessels) allows for **metastasis**, which is the most reliable criterion for distinguishing a malignant tumor from a benign one. [2] * **Rapid, erratic growth:** Malignant tumors generally have a higher proliferative index and a higher "growth fraction" compared to benign tumors, leading to faster and often unpredictable clinical progression. [3] **High-Yield Clinical Pearls for NEET-PG:** * **Exceptions to the rule:** While most benign tumors are encapsulated, some are not (e.g., **Hemangioma**, **Leiomyoma** of the uterus). [3] Conversely, some malignant tumors may appear "pseudocapsulated" (e.g., **Renal Cell Carcinoma** or **Follicular Thyroid Carcinoma**). * **Metastasis Rule:** All malignant tumors can metastasize EXCEPT **Basal Cell Carcinoma (BCC)** of the skin and **Gliomas** of the CNS (which are locally invasive but rarely spread distantly). * **Most reliable feature of malignancy:** Metastasis (followed by local invasion). [2] **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 204-206. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 278-280. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 276-278.
Practice by Chapter
Nomenclature and Classification of Tumors
Practice Questions
Characteristics of Benign and Malignant Neoplasms
Practice Questions
Molecular Basis of Cancer
Practice Questions
Carcinogenesis and Carcinogens
Practice Questions
Tumor Progression and Metastasis
Practice Questions
Tumor Markers
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Genetic Basis of Cancer
Practice Questions
Tumor Immunity
Practice Questions
Cancer Epidemiology and Prevention
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free